» Articles » PMID: 28560582

Towards Standardization of F-FET PET Imaging: Do We Need a Consistent Method of Background Activity Assessment?

Overview
Journal EJNMMI Res
Date 2017 Jun 1
PMID 28560582
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Background: PET with O-(2-F-fluoroethyl)-L-tyrosine (F-FET) has reached increasing clinical significance for patients with brain neoplasms. For quantification of standard PET-derived parameters such as the tumor-to-background ratio, the background activity is assessed using a region of interest (ROI) or volume of interest (VOI) in unaffected brain tissue. However, there is no standardized approach regarding the assessment of the background reference. Therefore, we evaluated the intra- and inter-reader variability of commonly applied approaches for clinical F-FET PET reading. The background activity of 20 F-FET PET scans was independently evaluated by 6 readers using a (i) simple 2D-ROI, (ii) spherical VOI with 3.0 cm diameter, and (iii) VOI consisting of crescent-shaped ROIs; each in the contralateral, non-affected hemisphere including white and gray matter in line with the European Association of Nuclear Medicine (EANM) and German guidelines. To assess intra-reader variability, each scan was evaluated 10 times by each reader. The coefficient of variation (CoV) was assessed for determination of intra- and inter-reader variability. In a second step, the best method was refined by instructions for a guided background activity assessment and validated by 10 further scans.

Results: Compared to the other approaches, the crescent-shaped VOIs revealed most stable results with the lowest intra-reader variabilities (median CoV 1.52%, spherical VOI 4.20%, 2D-ROI 3.69%; p < 0.001) and inter-reader variabilities (median CoV 2.14%, spherical VOI 4.02%, 2D-ROI 3.83%; p = 0.001). Using the guided background assessment, both intra-reader variabilities (median CoV 1.10%) and inter-reader variabilities (median CoV 1.19%) could be reduced even more.

Conclusions: The commonly applied methods for background activity assessment show different variability which might hamper F-FET PET quantification and comparability in multicenter settings. The proposed background activity assessment using a (guided) crescent-shaped VOI allows minimization of both intra- and inter-reader variability and might facilitate comprehensive methodological standardization of amino acid PET which is of interest in the light of the anticipated EANM technical guidelines.

Citing Articles

Comparison of F-FET-PET- and MRI-based target definition for re-irradiation treatment of recurrent diffuse glioma.

Everard A, Versnel D, Ruijters V, Tolboom N, Philippens M, Snijders T Clin Transl Radiat Oncol. 2025; 52:100931.

PMID: 40041678 PMC: 11879608. DOI: 10.1016/j.ctro.2025.100931.


Qualitative and quantitative analysis of 18F-GP1 positron emission tomography in thrombotic cardiovascular disease.

Whittington B, Tzolos E, Joshi S, Bing R, Andrews J, Loganath K Sci Rep. 2024; 14(1):26792.

PMID: 39500930 PMC: 11538255. DOI: 10.1038/s41598-024-77151-w.


Synthesis, preclinical assessment, and first-in-human study of [F]d-FET for brain tumor imaging.

Hou L, Chen Z, Chen F, Sheng L, Ye W, Dai Y Eur J Nucl Med Mol Imaging. 2024; 52(3):864-875.

PMID: 39482500 DOI: 10.1007/s00259-024-06964-8.


Pre-operative dual-time-point [F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study.

Lee D, Oh J, Kim J, Oh M, Oh S, Lee S Eur J Nucl Med Mol Imaging. 2024; 52(2):669-682.

PMID: 39365462 DOI: 10.1007/s00259-024-06935-z.


PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach.

Dadgar H, Jokar N, Nemati R, Larvie M, Assadi M Front Nucl Med. 2024; 3:1103262.

PMID: 39355049 PMC: 11440984. DOI: 10.3389/fnume.2023.1103262.


References
1.
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K . EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006; 33(11):1374-80. DOI: 10.1007/s00259-006-0206-3. View

2.
Hutterer M, Nowosielski M, Putzer D, Jansen N, Seiz M, Schocke M . [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013; 15(3):341-51. PMC: 3578481. DOI: 10.1093/neuonc/nos300. View

3.
Jansen N, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A . Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014; 55(2):198-203. DOI: 10.2967/jnumed.113.122333. View

4.
Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C . Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015; 25(10):3017-24. DOI: 10.1007/s00330-015-3691-6. View

5.
Niyazi M, Geisler J, Siefert A, Schwarz S, Ganswindt U, Garny S . FET-PET for malignant glioma treatment planning. Radiother Oncol. 2011; 99(1):44-8. DOI: 10.1016/j.radonc.2011.03.001. View